Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
oleh: Tiziano Bernasocchi, Geniver El Tekle, Marco Bolis, Azzurra Mutti, Arianna Vallerga, Laura P. Brandt, Filippo Spriano, Tanya Svinkina, Marita Zoma, Valentina Ceserani, Anna Rinaldi, Hana Janouskova, Daniela Bossi, Manuela Cavalli, Simone Mosole, Roger Geiger, Ze Dong, Cai-Guang Yang, Domenico Albino, Andrea Rinaldi, Peter Schraml, Simon Linder, Giuseppina M. Carbone, Andrea Alimonti, Francesco Bertoni, Holger Moch, Steven A. Carr, Wilbert Zwart, Marianna Kruithof-de Julio, Mark A. Rubin, Namrata D. Udeshi, Jean-Philippe P. Theurillat
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2021-02-01 |
Deskripsi
Gene fusions involving the ERG transcription factor and point mutations in the ubiquitin ligase adaptor SPOP are two truncal mutations that are mutually exclusively present in prostate cancer. Here, the authors show that mutations in SPOP render prostate tumor cells sensitive to antiandrogen therapy and that the presence of ERG promotes sensitivity to high dose of androgen and SPOP inhibition.